Skip to main content

Table 1 Principal characteristics of Trial Based Economic Evaluations comparing MEBO.

From: Comparing oil based ointment versus standard practice for the treatment of moderate burns in Greece: a trial based cost effectiveness evaluation

Author and country

Patient group

Study type, setting and perspective

Comparators

Main results

1) Ang et al, 2001 Singapore

115 (started) patients (6-80 years) with partial thickness (TBSA: < 40%) burns to the face excluding chemical and electrical burns.

Cost consequences, single centre study, secondary care. Perspective adopted: health care system

Silver sulfadiazine cream (C)

The median time to 75% healing was 17.0 and 20.0 days in MEBO and conventional therapy groups, respectively (Hazard Ratio: HR: 0.67; 95% CI: 0.41-1.11; p = 0.11), (similar efficacy). Bacterial infection rates were similar between the two groups (HR: 1.10; 95% CI: 0.59-2.03; p = 0.76). MEBO imparted a greater analgesic effect in the first 5 days of therapy and reduced hospital costs by 8%

2) Atiyeh B. S. et al, Egypt, 2002

40 patients between (5-54 years) with superficial partial thickness burns 5-20% TBSA in adults and 5-15% TBSA in children, excluding chemical and electrical burns and patients with visual, mental or physical disabilities pregnant or lactating women as females at pregnancy risk.

Cost Benefit under a clinical prospective multi-center (five centers) study, secondary care. Perspective adopted: health care system

Silver sulphadiazine, Sofratulle Chlorhexidinetulle, Nitrofurazone, Quadriderm (betamethasone + chlorocresol+clioquinol +gentamicin+tolnaftate), Dexpanthenol, NitrofurazoneSavlon (cetrimide + chlorhexidine) Hydrogen peroxide Povidone-iodine

Patients not treated with MEBO application required statistically significant (p < 0.01) longer hospitalization. (30%) The time spent by nurses (p < 0.01) and doctors (p < 0.05), were significantly lower in MEBO as well as overall direct costs (p < 0.01.)

3) Atiyeh B. S. et al., 2004, Saudi Arabia

52 (started) patients (2-58 years) with a second degree TBSA burns of 5 to 35% burn (> 15% TBSA for children and > 20% for adults), excluding chemical and electrical burns

Cost consequences under a clinical prospective multi-center (14 centers) study, secondary care. Perspective adopted: health care system

Silver Sulfadiazine, Extract cepae 10%, heparin sodium 5000 iu and allantion, Panothenic acid, Chlorohexidine, Fucidic acid Bacitracin zinc and neomycin sulphate, Povidone iodine, Sofratulle.

Significant differences in favour of MEBO group concerning the reduction of 20.24% in hospitalization time (p = 0.0056), the total hospitalization cost (p = 0.025), the total time spent by physicians and nurses, the analgesic cost per day reduced by 60.8%) per course (p = 0.0135) and 55.88% per day (p = 0.0271). The other differences aren't significant.